Consumer Reps Join ODAC Meetings

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 4
Volume 4
Issue 4

ROCKVILLE, Md--In February, as part of an FDA pilot program, representatives of consumer groups sat at the table during an Oncologic Drugs Advisory Committee (ODAC) meeting. The ad hoc representatives from the Treatment Action Group, a New York organization representing people with AIDS, and the National Breast Cancer Coalition participated in the discussions of New Drug Applications but did not have a vote.

ROCKVILLE, Md--In February, as part of an FDA pilot program, representativesof consumer groups sat at the table during an Oncologic DrugsAdvisory Committee (ODAC) meeting. The ad hoc representativesfrom the Treatment Action Group, a New York organization representingpeople with AIDS, and the National Breast Cancer Coalition participatedin the discussions of New Drug Applications but did not have avote.

According to Randy Wykoff, MD, FDA associate commissioner forAIDS and special health issues, the pilot program is a responseto requests from cancer advocacy groups. Different representativeswill be chosen for each NDA that ODAC reviews. ODAC often asksnon-voting medical and /or scientific consultants to help reviewNDAs; consumer advocates would serve a simular function, Dr. Wykoffsaid.

Recent Videos
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
A collaboration between the Connecticut Departments of Health and Corrections and the COPPER Center aimed to improve outcomes among incarcerated patients.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
4 experts are featured in this series.
4 experts are featured in this series.
Related Content